Progyny, Inc. Stock Price, News & Analysis

Progyny, Inc. (PGNY) reported record second quarter revenue of $128.7 million, reflecting a remarkable 99% growth year-over-year. The surge in demand for fertility benefits led to increased client numbers, with 182 clients as of June 30, 2021. Gross profit reached $29.6 million, a 148% increase, while net income soared to $18.7 million, compared to a loss in the prior year. The company anticipates revenue of $510 million to $530 million for the full year 2021, marking a projected 48% to 54% growth.

Progyny (Nasdaq: PGNY), a leader in fertility benefits management, will report its financial results for the quarter ended June 30, 2021, on August 5, 2021. The results will be disclosed after market close, followed by a conference call at 4:45 PM Eastern Time. U.S. participants can access the call by calling 1.866.825.7331, while international callers may use 1.973.413.6106. An audio replay will be available until August 12, 2021. Progyny aims to redefine fertility solutions, benefiting employers, patients, and physicians.

Progyny, a leader in fertility benefits management, announced participation in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 3:50 PM ET. CEO David Schlanger and CFO Mark Livingston will engage in a fireside chat, highlighting the company's innovative approach to family building benefits. A live audiocast will be accessible via the Events and Presentations section on Progyny's website. Progyny is recognized for redefining fertility solutions, benefiting patients and employers while driving clinical outcomes.

Progyny, Inc. (Nasdaq: PGNY) partnered with RMA of Connecticut, RMA of New York, and Stanford University to conduct the largest study focusing on single or coupled intended fathers using assisted reproductive technology (ART). The multi-center study analyzed 119 participants and highlighted that 95.2% desired at least 2 children and 72.5% planned to use an egg donor agency. Key findings presented at two conferences showed that SCIFs had an 85.2% success rate for live births when using specific treatment strategies. The study emphasizes the growing demand for fertility treatments among this demographic and the need for comprehensive employer support.

Welltok has integrated Maven and Progyny into its Connect Partner Ecosystem, enhancing employer offerings for family planning and fertility benefits. The inclusion aims to attract and retain talent by providing comprehensive fertility programs. Maven delivers personalized maternity support, resulting in a 90% return-to-work rate and 32% fewer NICU admissions. Progyny boasts a 25% higher live birth rate than national averages and significantly reduces healthcare costs. This partnership underscores Welltok's commitment to improving maternal health and supporting diverse family-building needs.

Progyny, a leader in fertility benefits management, announced that CEO David Schlanger and CFO Mark Livingston will engage in a fireside chat at the BofA Securities 2021 Health Care Conference on May 12, 2021, at 10:15 A.M. ET. The discussion aims to highlight Progyny's innovative fertility solutions and their impact on employers and patients. A live audiocast and replay will be available on Progyny’s investor website. The company, headquartered in New York City, has received accolades for its growth and leadership in redefining family building benefits.

Progyny, Inc. (PGNY) reported a record revenue of $122.1 million for Q1 2021, marking a 51% increase from the previous year. This growth is attributed to a higher client base and demand for fertility benefits. The company has issued a revenue guidance of $126.0 million to $131.0 million for Q2 2021, reflecting a growth of 95% to 103%. Net income surged to $15.2 million, up 318% year-over-year. Progyny's solid financial performance is complemented by increased operating efficiencies and positive industry trends.

Progyny, Inc. (Nasdaq: PGNY) will report its financial results for Q1 2021 on May 6, 2021, after market close. The company specializes in fertility and family building benefits. A conference call will follow at 4:45 PM ET, with access details for both U.S. and international participants provided. An audio replay will be available until May 14, 2021. Progyny is recognized for its innovative approach in the fertility sector, supporting patients and employers alike. Further information can be found on their website.

Progyny, Inc. (Nasdaq: PGNY) reported a record revenue of $100.3 million for Q4 2020, a 54% increase from Q4 2019. For FY 2020, total revenue reached $344.9 million, up 50% year-over-year. The company also projected 2021 revenue between $520 million and $540 million, reflecting growth of 51% to 57%. Key highlights included a tripled Adjusted EBITDA and significant growth in both fertility and pharmacy benefit services. Despite challenges from the COVID-19 pandemic, Progyny's performance showcased its market resilience and expansion capabilities.